MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired last year in a $1.7 billion deal. This consolidation of research operations will result in a non-cash impairment charge on Constellation’s goodwill.
